Encorafenib, Binimetinib, and Cetuximab in BRAF V600E…
Sep 29, 2019 · In this open-label, phase 3 trial, we enrolled 665 patients with BRAF V600E–mutated metastatic colorectal cancer who had had disease progression after one or …
Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer ...
Sep 23, 2024 · A phase Ib/II trial of combined BRAF and EGFR inhibition in BRAF V600E positive metastatic colorectal cancer and other cancers: the EVICT (Erlotinib and Vemurafenib In …
Management of BRAF-mutant metastatic colorectal cancer: a review …
Apr 6, 2021 · Herein, we review the clinical and translational literature on the role of the BRAF V600E mutation in the pathogenesis of mCRC, its mechanisms as a prognostic marker, and its …
Phase III trial results supported recent FDA approval for patients …
5 days ago · Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefitted from first-line treatment with the targeted therapies encorafenib and cetuximab plus …
Treating Patients With MSI-H BRAFV600E-Mutated Metastatic Colorectal Cancer
Mar 10, 2022 · One-fourth of BRAFV600E metastatic colorectal cancer (mCRC) are microsatellite instability–high (MSI-H), and one-fifth of MSI-H mCRC display the BRAFV600E mutation (MSI …
The Evolving Treatment Landscape in BRAF-V600E–Mutated …
May 3, 2022 · Novel approaches for managing BRAF-V600E metastatic colorectal cancer include combinations of BRAF inhibitors and anti-EGFR antibodies with immune checkpoint inhibitors. …
Real-world first-line treatment of patients with BRAF V600E
BRAFV600E mutations occur in 8%-12% of metastatic colorectal cancer (mCRC) cases and are associated with poor survival. European guidelines recommend combination (doublet or triplet) …
Combined PD-1, BRAF and MEK inhibition in BRAF V600E colorectal cancer ...
Jan 26, 2023 · BRAF V600E mutations occur in ~10% of colorectal cancer (CRC), driving constitutive activation of MAPK signaling. Patients with BRAF V600E CRC have unfavorable …
Targeting BRAF V600E in metastatic colorectal cancer: where are …
Tabernero J, Grothey A, Van Cutsem E, et al. Encorafenib plus cetuximab as a new standard of care for previously treated BRAF V600E-mutant metastatic colorectal cancer: updated survival …
Updates in BRAF V600E -Mutated Metastatic Colorectal Cancer
Mar 19, 2024 · The BRAF V600E mutation occurs in 8–12% of patients with metastatic colorectal cancer (mCRC), and is characterised by an aggressive clinical course and poor prognosis.